Covid-19 roundup: FDA stamps quick OK on Roche's Actem­ra PhI­II; AlloVir ex­pands Bay­lor pact

→ The FDA has of­fered a quick OK for Genen­tech to start a Phase III tri­al us­ing their rheuma­toid arthri­tis drug Actem­ra against Covid-19. And the big Roche sub­sidiary is send­ing in 10,000 dos­es for the US stock­pile.

Genen­tech is work­ing with BAR­DA on the study, which has es­tab­lished pri­ma­ry and sec­ondary end­points that in­clude “clin­i­cal sta­tus, mor­tal­i­ty, me­chan­i­cal ven­ti­la­tion and in­ten­sive care unit (ICU) vari­ables.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.